We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+8.13%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$988M
AUM Growth
-$31.3M
Cap. Flow
-$56.5M
Cap. Flow %
-5.72%
Top 10 Hldgs %
45.25%
Holding
164
New
47
Increased
25
Reduced
25
Closed
38

Top Buys

Rank Stock Value
1
OTIC
Otonomy, Inc.
OTIC
+$16.6M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$11.4M
3
ARWR icon
Arrowhead Research
ARWR
+$11.3M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.4M
5
EPZM
Epizyme, Inc
EPZM
+$7.5M

Top Sells

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$37M
2
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$24.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.9M
4
SHPG
Shire pic
SHPG
+$21.2M
5
INSM icon
Insmed
INSM
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 79.83%
2 Financials 0.18%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPNC
51
DELISTED
Spectranetics Corp
SPNC
$3.68M 0.37%
138,371
-104,983
-43% -$2.82M
AGN
52
DELISTED
Allergan plc
AGN
$3.62M 0.37%
+15,000
New +$3.36M
CMRX
53
DELISTED
Chimerix, Inc.
CMRX
$3.54M 0.36%
128,000
-20,000
-14% -$486K
VCEL icon
54
Vericel Corp
VCEL
$2.38B
$3.13M 0.32%
+1,100,000
New +$3.64M
WBA
55
DELISTED
Walgreens Boots Alliance
WBA
$2.96M 0.3%
50,000
-232,000
-82% -$15.2M
PFNX
56
DELISTED
Pfenex Inc.
PFNX
$2.94M 0.3%
+400,000
New +$2.56M
VIRX
57
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.86M 0.29%
+1,905
New +$2.76M
VIRX
58
PUT
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.86M 0.29%
+1,905
New +$2.76M
KERX
59
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.75M 0.28%
+200,000
New +$3.06M
ELDN icon
60
Eledon Pharmaceuticals
ELDN
$255M
$2.73M 0.28%
+1,111
New +$3.16M
PBYI icon
61
Puma Biotechnology
PBYI
$398M
$2.62M 0.27%
+11,000
New +$2.26M
ASPX
62
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$2.57M 0.26%
+100,000
New +$2.13M
QTNT
63
DELISTED
Quotient Limited Ordinary Shares
QTNT
$2.49M 0.25%
6,596
-904
-12% -$330K
LJPC
64
DELISTED
La Jolla Pharmaceutical Company
LJPC
$2.4M 0.24%
+250,000
New +$2.49M
VTRS icon
65
Viatris
VTRS
$20.8B
$2.27M 0.23%
50,000
-232,500
-82% -$11.3M
MGCD
66
DELISTED
MGC Diagnostics Corporation
MGCD
$2.23M 0.23%
327,488
+11,029
+3% +$85.4K
ARDX icon
67
Ardelyx
ARDX
$1.24B
$2.17M 0.22%
+153,077
New +$2.21M
GRCE
68
Grace Therapeutics
GRCE
$33.8M
$1.98M 0.2%
5,362
+15
+0.3% +$7.05K
DSCI
69
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.8M 0.18%
215,809
-190,628
-47% -$1.77M
FPRX
70
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.76M 0.18%
150,000
– –
UPI
71
DELISTED
UROPLASTY INC-NEW
UPI
$1.74M 0.18%
697,287
+29,000
+4% +$75.7K
PRQR icon
72
ProQR Therapeutics
PRQR
$244M
$1.72M 0.17%
+100,000
New +$1.6M
GNVC
73
DELISTED
GenVec, Inc.
GNVC
$1.71M 0.17%
82,000
– –
ACHN
74
DELISTED
Achillion Pharmaceuticals
ACHN
$1.7M 0.17%
170,000
-110,000
-39% -$1.02M
BFYT
75
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
$1.59M 0.16%
+131,025
New +$1.63M
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2014 Portfolio in Review

As of Q3 2014, Perceptive Advisors held 164 positions worth $988M, down 3.1% from $1.02B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors withdrew a net $56.5M in Q3 2014, closing 38 positions and reducing 25 holdings. Its most notable exit was QUESTCOR PHARMA INC, an estimated $37M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 81% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Perceptive Advisors opened a new position in Otonomy, Inc. worth $20.1M.

  • Perceptive Advisors's largest Q3 2014 buy was Otonomy, Inc.: 837,400 shares worth $20.1M.
  • Perceptive Advisors added most to Arrowhead Research in Q3 2014, an estimated $11.3M increase.
  • Perceptive Advisors's biggest Q3 2014 reduction was Taro Pharmaceutical Industries Ltd., cutting an estimated $24.1M.
  • Perceptive Advisors fully exited QUESTCOR PHARMA INC in Q3 2014, selling an estimated $37M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $988M portfolio in Q3 2014.
  • Perceptive Advisors opened 47 new positions and closed 38 in Q3 2014.
  • Perceptive Advisors's portfolio value fell 3.1% quarter-over-quarter to $988M.

Based on Perceptive Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.